Categories Consumer, Earnings

Vail Resorts delivers a mixed bag in Q3, stock buoyed by earnings beat

Travel and leisure company Vail Resorts (NYSE: MTN) reported third-quarter revenues that grew 13.7% to $957.9 million, narrowly missing the market projection of $958.75 million. Earnings for the quarter grew to $7.12 per share, from $6.17 per share a year ago. The Q2 earnings were stronger than the analysts’ expectation of $7.06 per share.

Vail shares jumped over 6% following the earnings announcement. MTN shares have declined 16.6% in the trailing 52 weeks, though it has pared some of the losses this year. For the year-to-date period, the stock is up 2%.

vail resorts earnings
Image courtesy: Vail Resorts

The company narrowed its full-year 2019 earnings outlook to $277-297 million, from the earlier guidance of $268-$300 million. Resort-reported EBITDA guidance was slightly raised to $702-712 million, from the prior guidance of $690-710 million, to take into account the recent acquisitions.

Earlier this quarter, Vail announced the closure of its acquisition of the ski field leases and related infrastructure at Falls Creek Alpine Resort and Hotham Alpine Resort in Victoria, Australia, for approximately $127 million.  

READ: Who will take over the video streaming realm? Disney or Netflix

For fiscal 2019, Falls Creek and Hotham resorts are expected to contribute approximately $2 million of Resort Reported EBITDA.

In Q3, total lift revenue increased 16.4%, driven by a 14.3% growth in skier visitation primarily from Triple Peaks and Stevens Pass. Total effective ticket price increased 1.8% in the third quarter compared to the prior year, primarily due to price increases in both lift ticket and season pass products.  

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Everything you need to know about Aktis Oncology’s upcoming IPO

IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology, which develops radiopharmaceuticals for solid tumors, is the

Constellation Brands set to report Q3 2026 earnings. Here’s what to expect

Constellation Brands' (NYSE: STZ) performance across its portfolio has been under scrutiny recently as it navigates a challenging consumer environment marked by sluggish demand and competitive pressures. With the beer

Broadcom Stock: Valuation and margins under review amid AI tailwinds

Broadcom, Inc. (NASDAQ: AVGO) has emerged as a key AI infrastructure supplier, leveraging its expertise in custom AI accelerators, to expand beyond its legacy smartphone and storage chip businesses. However,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top